U.S. law makers have asked Gilead for information on discounts for its new hepatitis C drug, Sovaldi, which can cost more than $80,000 per person. Sovaldi is the first oral medication for treatment of hepatitis C virus which showed high cure rates of over 90% in clinical trials while older drugs have cure rates at about 75%. The major concern from lawmakers is that the treatment would not be able to cure patients if patients aren’t able to afford it.
What do you do when the copays for a medication is too expensive for the patient to afford?
For additional information, please visit Reuters
Image courtesy of [amenic181]/FreeDigitalPhotos.net